FSM uses two simultaneous frequencies — one targeting a physiological condition, one targeting a specific tissue type. Here’s how it works, what the science supports, and how to think about it as a wellness tool.
What Makes FSM Different From Standard Microcurrent
Standard microcurrent delivers a single channel of subsensory electrical current at a fixed frequency to support tissue recovery and reduce inflammation. FSM builds on this with a second layer of precision: two simultaneous channels of current, each tuned to a specific frequency, working together on a defined physiological target.
If you’re new to microcurrent, the introduction to microcurrent therapy is a good starting point. The core concepts — ATP production, subsensory current, how it differs from TENS — are covered there.
General microcurrent research and FSM-specific research are not the same thing. Studies on microcurrent broadly tell us that subsensory electrical current produces measurable biological effects. They don’t tell us whether the two-channel, frequency-paired approach produces different outcomes from standard single-channel delivery. The broader microcurrent literature supports the modality class; FSM’s claim that paired frequencies produce tissue-specific outcomes is a separate question with its own, still-developing evidence base. The evidence sections below draw this line clearly.
How the Two Channels Work
Channel A — The Condition
Set to a frequency historically associated with a specific physiological process — such as inflammation, scar tissue, or nerve irritation.
Channel B — The Tissue
Set to a frequency associated with a specific tissue type — muscle, nerve, fascia, or a specific organ.
The two channels run simultaneously. A practitioner selects frequency pairs based on the clinical presentation. The frequency lists that specify which Hz values correspond to which tissues and conditions were developed empirically over decades of clinical practice — not derived from laboratory experiments.
The Resonance Hypothesis
The proposed mechanism behind FSM’s frequency specificity is called the resonance hypothesis: that applied current resonates with charged particles or dipoles within specific tissues when the applied frequency matches a characteristic frequency of that tissue — similar in concept to how a tuning fork causes a matching string to vibrate while others stay still.
Independent laboratory research lends biological plausibility to this idea. Studies from a university physiology department found that low-level pulsed electrical fields in the microcurrent frequency range activate membrane signal-transduction proteins, trigger calcium ion influx, and measurably alter cellular ATP levels and purinergic signaling pathways. These are findings from researchers with no FSM affiliation, demonstrating that electrical field frequency can selectively modulate specific molecular cascades at the cellular level.
A Brief History of FSM
The frequency lists used in FSM trace their origins to early 20th-century electrotherapy practice, preserved through practitioners including Harry Van Gelder and George Douglas. Dr. Carolyn McMakin — a chiropractor in Portland, Oregon — substantially revised and expanded this work beginning in 1995–1997, developing the two-channel delivery methodology and clinical training curriculum that defines FSM practice today.
The full history of the frequency lineage and how the training program evolved is documented at frequencyspecific.com.
What FSM Is Used For
FSM is applied across a wide range of presentations in integrative and functional medicine practice. The tier labels below reflect where research currently stands — not where clinical practice stands, which is often ahead of the controlled literature.
Musculoskeletal Pain and Injury Recovery
This is the best-supported application area. The landmark controlled trial compared one leg receiving FSM after maximal eccentric exercise to the other leg as an untreated control. Delayed onset muscle soreness was dramatically lower in the treated leg at 24, 48, and 72 hours — with statistically significant results and large effect sizes.
A large case-control study comparing FSM patients to controls receiving standard physical rehabilitation found significantly better pain and disability outcomes for the FSM group in low back pain. A 2022 crossover trial found better self-rated recovery and reduced exhaustion after FSM versus sham in resistance training. Case-level evidence also supports joint applications including knee osteoarthritis.
An earlier body of clinical case work adds historical depth. McMakin’s 1998 case review of 50 patients with resistant chronic head, neck, and face myofascial pain reported lasting pain reduction in 49 of 50 cases after a mean of 11.2 treatments over 7.9 weeks. A 2004 retrospective case series of 22 chronic low-back pain patients — 90% of whom had failed prior therapies — reported a nearly 4-fold VAS reduction. A 2017 case report documents resolution of chronic pain and hyperesthesia after ulnar nerve transposition surgery in just three FSM sessions.
The controlled evidence base consists of one randomized trial, one large retrospective case-control study, and one small crossover trial. Independent replication with larger samples is still needed.
Fibromyalgia
The most cited FSM fibromyalgia study measured cytokine levels in patients with fibromyalgia associated with cervical trauma. Substantial reductions in inflammatory markers — including IL-1, IL-6, TNF-alpha, and substance P — were observed alongside increased beta-endorphins. These are meaningful biomarker findings, though the cytokine analysis involved a small sample and the study was uncontrolled.
For broader context: a 2023 network meta-analysis covering over 3,000 patients ranked general microcurrent as the most effective electrophysical agent for fibromyalgia pain and mood. That evidence speaks to microcurrent broadly — not FSM specifically — but supports the biological plausibility of the approach.
No controlled FSM trial for fibromyalgia has been conducted. The evidence is promising but preliminary.
Neuropathic Discomfort and Nerve-Related Applications
FSM is used clinically for nerve-related discomfort including neuropathy, post-surgical nerve pain, and nerve entrapment. Its clinical rationale rests on Channel B’s ability to target specific nerve tissue — a more precise approach than generic microcurrent.
A case series from Walter Reed National Military Medical Center documented rapid pain reduction and improvement in neurological and emotional symptoms in patients with complex traumatic injury presentations. Clinical retrospective data also supports FSM use for monoradicular neuropathic pain, with reported resolution or significant reduction in the majority of cases. A 2025 case report extends FSM’s applications into hypermobility spectrum disorder, describing symptom improvement including reduced pain and improved stress response.
Worth noting: general microcurrent showed no superiority over placebo for diabetic neuropathy in one randomized trial — microcurrent is not universally effective for nerve pain. FSM-specific controlled trials for neuropathy have not been conducted.
Ophthalmic Applications
A 2015 IRB-approved open-label pilot study (17 patients, 31 eyes) examined FSM using transpalpebral microcurrent at 150 µA for age-related macular degeneration. Visual acuity improved significantly in dry AMD (p<0.012); wet AMD trended positive but did not reach significance. The trial was registered (NCT01790958) and used standardized ophthalmic outcomes — making it methodologically stronger than most FSM pilot work, though it lacks a control group.
A single uncontrolled pilot is not sufficient to establish efficacy. It warrants a controlled follow-up trial.
Scar Tissue and Fibrosis
Tissue softening is one of the most consistently reported clinical phenomena in FSM practice. Practitioners document palpable changes in tissue consistency within seconds to minutes of applying appropriate frequency pairs.
The strongest controlled clinical evidence that microcurrent can physically reduce fibrotic tissue comes from a peer-reviewed pilot study in 26 head-and-neck cancer patients with radiation-induced fibrosis. After one week of microcurrent therapy, 92% showed improved cervical rotation; most maintained those gains at three months. This was general microcurrent — but it provides clinical credibility to the tissue-softening mechanism.
Visceral and Autonomic Applications
FSM is used in advanced clinical practice for visceral organ support and autonomic nervous system regulation. These applications are practitioner-guided, require FSM Core Training, and are categorized Tier 2–3 because the evidence — while including peer-reviewed mechanistic discussion and clinical observation — does not yet include controlled trials.
These applications require practitioner oversight. FSM-specific controlled trials in this area have not been conducted.
Stress, Mood, and Connective Tissue Disorders
Two 2025 studies from independent research groups represent a meaningful step forward for the FSM evidence base. A four-arm pilot randomized controlled trial from the University of Minho, Portugal compared FSM alone, FSM with relaxation, relaxation alone, and placebo across 58 participants. FSM participants reported fewer somatic symptoms and negative emotions than the relaxation-only group at six sessions.
A separate pilot study in 17 patients with systemic sclerosis found a 40% mean improvement in hand function and significant improvement in Raynaud’s symptoms. Both studies warrant follow-up controlled trials.
The Evidence Picture
FSM has a growing, peer-reviewed evidence base. Most studies are pilot-level. The most important distinction to hold: general microcurrent evidence and FSM-specific evidence are two separate bodies of literature. The broader microcurrent literature supports the modality class at Tier 2 — wound healing, pressure ulcers, selected musculoskeletal pain. FSM’s specific claim that paired frequencies produce distinct tissue-targeted outcomes is a narrower, still-developing question sitting mostly at Tier 3, with narrow Tier 2 pockets in DOMS, low-back rehabilitation, distress, and scleroderma hand function.
Across the full FSM-specific corpus, there is currently no Tier 1 evidence — no multicenter, independently replicated, systematic-review-grade evidence base. The field is genuinely emerging, with a growing trial registry pipeline and the first independently conducted RCTs appearing in 2025.
All Studies at a Glance
| Study | Key Finding | Design |
|---|---|---|
| Curtis et al. 2010 | DOMS pain dramatically lower at 24h, 48h, 72h — large effect sizes | RCT · n=35 |
| Shetty et al. 2020 | Lower pain and disability in low back pain vs. standard rehabilitation | Case-control · n=291 |
| Stösslein & Kuypers 2022 | Better recovery, reduced exhaustion, improved mood post-resistance training | Crossover RCT · n=20 |
| Pereira et al. 2025 | Fewer somatic symptoms and improved stress vs. relaxation-only — independent group | Pilot RCT · n=58 · 4-arm |
| Gregory et al. 2025 | 40% hand function improvement in scleroderma; Raynaud’s scores improved | Pilot · n=17 |
| McMakin & Oschman 2013 | Tissue softening mechanism described; resonance hypothesis articulated | Mechanistic review |
| Sharp et al. 2019 | Pain reduction and neurological symptom improvement in wounded warriors | Case series · n=3 |
| Thompson & Kaplan 2019 | Full range of motion restored in grade 8 torticollis; fibrotic nodules resolved | Case report · n=1 |
| Chaikin et al. 2015 | 52% visual acuity improvement in dry AMD; 83% improved in wet AMD | Pilot · n=17 |
| Seegers et al. 2001 & 2002 | Pulsed electric fields activate cellular signal transduction and increase ATP 163% — independent laboratory | In vitro + human plasma |
| Lennox et al. 2002 | 92% improved cervical rotation in radiation-induced fibrosis after one week microcurrent | Clinical pilot · n=26 |
| Iijima & Takahashi 2021 | Significant shoulder pain improvement; signals for other musculoskeletal indications | Systematic review · 9 studies |
| Avendaño-Coy et al. 2022 | Microcurrent effective for wound area reduction, healing time, and pain | Systematic review + meta-analysis |
| Ranker et al. 2020 | Microcurrent beneficial for knee OA pain not explained by placebo | Sham-controlled RCT |
The Research Pipeline
NCT04617197 — Chronic Low Back Pain (Taipei Medical University): A completed double-blind, placebo-controlled trial comparing two FSM frequency combinations versus placebo in 60 participants. This is the most rigorous FSM trial to date. Results have not yet been published.
NCT06390137 — Anti-Inflammatory Effects in Osteoarthritic Adults: Examines immunomodulatory effects of FSM in osteoarthritis. Registry records indicate completion; verify status at ClinicalTrials.gov.
NCT06245967 — Mild Traumatic Brain Injury: An ongoing trial examining FSM for mTBI — a meaningful extension into neurorehabilitation.
NCT04060563 — Diastasis Recti: A registered trial examining FSM for postpartum diastasis recti.
Who Delivers FSM and Which Devices Are Used
In Clinical Settings
In-clinic FSM is delivered by licensed practitioners with electrical stimulation within their scope of practice — including MDs, DCs, PTs, NDs, NPs, LAcs, and LMTs where electrotherapy falls within their state scope. FSM Core Training is strongly recommended. Full training details at frequencyspecific.com.
Home and Wellness Devices
Three device pathways bring FSM frequencies into the home setting. They fall into two distinct categories — and the difference matters for how you access and use each one.
Cleared as Class II TENS devices for pain management. Require a licensed practitioner prescription to obtain.
CustomCare (Precision Distributing)
Practitioner-programmed with up to 45 custom protocols. FDA cleared, CE Mark, ISO 13485 certified. FSM Core Training required. Pricing on inquiry only — contact Max.
HoweRT Micro-Sport
Pre-programmed clinical protocols developed by Vanessa Howe MSPT. FDA cleared. No Core Training required. Pricing on inquiry only — contact Max.
Deliver FSM frequencies via PEMF — same frequency logic, different delivery physics. More accessible, no prescription needed.
iCare PEMF Platform
App-based PEMF delivery of FSM frequencies. Foundational packages available to all users. Custom programming done with practitioner guidance. Contact Max to learn more.
Infopathy Platform
Multi-modal platform delivering FSM-compatible frequencies. Fully self-customizable from the IC library — no consultation required for any level of use.
For a full comparison of iCare and Infopathy as complementary tools, see the iCare vs. Infopathy page.
Contraindications
- Pacemakers or implanted electronic devices — electrical current may interfere with device function
- Pregnancy — electrical stimulation is contraindicated
- Active cancer — particularly near tumor sites; discuss with your oncologist
- Organ transplant — do not use
- Active infection — anti-inflammatory frequencies will reduce inflammation even when infection is present; the infection can worsen while inflammation is suppressed
- Insulin-dependent diabetes — do not treat the pancreas; FSM can improve insulin production which may cause dangerous hypoglycemia when combined with injected insulin
- Seizure history or epilepsy — electrical stimulation may lower seizure threshold
- Dehydration — patients who are dehydrated cannot benefit from FSM or microcurrent; drink at least one quart of water in the four hours before treatment
- Within 6 weeks of a new injury — the scar tissue removal frequency (13/) should not be used; newly injured tissue must form scar tissue to repair itself
- Over the carotid sinus — can affect blood pressure and heart rate
- Uncontrolled atrial fibrillation — use caution
- Acute fever or active febrile illness — do not use
Contraindications sourced from frequencyspecific.com and the FSM Core Training curriculum. This list is not exhaustive. Always consult a qualified healthcare provider before beginning FSM or any electrotherapy modality, especially if you have existing health conditions or take medications.
References
All citations link directly to their source. For the complete annotated evidence library, see the Research & Evidence Library.
FSM-Specific Studies
- Gregory WM, et al. Frequency-specific microcurrent improves hand function and Raynaud’s symptoms in scleroderma. Rheumatology (Oxford). 2025;64(10):5504–5508. PubMed
- Pereira MG, et al. Effectiveness of FSM Therapy and Relaxation in Adults with Distress: A Pilot RCT. Healthcare (Basel). 2025;13(10):1151. PubMed
- Stösslein BAC, Kuypers KPC. Self-Rated Recovery and Mood Before and After Resistance Training and Muscle Microcurrent Application. Frontiers in Psychology. 2022;13:836695. PubMed
- Shetty GM, et al. Effect of adjuvant frequency-specific microcurrents on pain and disability. J Bodywork Mov Ther. 2020;24(4):168–175. PubMed
- Sharp SJ, et al. FSM as Adjunctive Therapy for Three Wounded Warriors. Medical Acupuncture. 2019;31(3):189–192. PubMed
- Thompson R, Kaplan SL. FSM for Treatment of Longstanding Congenital Muscular Torticollis. Pediatric Physical Therapy. 2019;31(2):E8–E15. PubMed
- Chaikin L, et al. Microcurrent stimulation in the treatment of dry and wet macular degeneration. Clinical Ophthalmology. 2015;9:2345–2353. NCT01790958. PubMed
- McMakin CR, Oschman JL. Visceral and somatic disorders: tissue softening with frequency-specific microcurrent. J Alt Complement Med. 2013;19(2):170–177. PubMed
- Curtis D, et al. The efficacy of FSM therapy on delayed onset muscle soreness. J Bodywork Mov Ther. 2010;14(3):272–279. PubMed
- McMakin CR, et al. Cytokine changes with microcurrent treatment of fibromyalgia associated with cervical spine trauma. J Bodywork Mov Ther. 2005;9(3):169–176.
- McMakin CR. Nonpharmacologic treatment of neuropathic pain using frequency specific microcurrent. The Pain Practitioner. 2010;Fall:68–73.
- McMakin CR. Microcurrent therapy: a novel treatment method for chronic low back myofascial pain. J Bodywork Mov Ther. 2004;8(2):143–153.
Mechanistic Studies
- Seegers JC, et al. Activation of signal-transduction mechanisms may underlie therapeutic effects of an applied electric field. Medical Hypotheses. 2001;57(2):224–230. PubMed
- Cheng N, et al. The effects of electric currents on ATP generation, protein synthesis, and membrane transport in rat skin. Clin Orthop Relat Res. 1982;(171):264–272. PubMed
- Konstantinou EK, et al. Microcurrent stimulation triggers MAPK signaling and TGF-β1 secretion. Bioelectromagnetics. 2020;41(6):421–430.
Broader Microcurrent Evidence (Modality Class)
- Iijima H, Takahashi M. Microcurrent Therapy as a Therapeutic Modality for Musculoskeletal Pain: A Systematic Review. Arch Rehabil Res Clin Transl. 2021;3(3):100145. PubMed
- Avendaño-Coy J, et al. Electrical microcurrent stimulation therapy for wound healing: a meta-analysis of RCTs. J Tissue Viability. 2022;31(1):63–69. PubMed
- Arora M, et al. Electrical stimulation for treating pressure ulcers. Cochrane Database Syst Rev. 2020;1:CD012196. PubMed
- Ranker A, et al. Microcurrent therapy in the treatment of knee osteoarthritis. Bioelectromagnetics. 2020;41(5):349–360. PubMed
- Gikaro JM, et al. Efficacy of electrophysical agents in fibromyalgia: Network meta-analysis. Clinical Rehabilitation. 2023;37(10):1295–1310. PubMed
- Lennox AJ, et al. Pilot study of impedance-controlled microcurrent therapy for radiation-induced fibrosis. Int J Radiat Oncol Biol Phys. 2002;54(1):23–34. PubMed